Calcitonin load test to assess the efficacy of salmon calcitonin

Clinica Chimica Acta

Volumn 336, Issue 1-2, 2003, Pages 49-55

  Stepan, Jan J ^a   Zikán, Vít ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biochemical markers; Calcitonin; Collagen I; Monitoring; Osteoporosis

Indexed keywords

SALCATONIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FEMUR NECK; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0142153970     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00332-2     Document Type: Article

References (29)

1. Zaidi M., Alam A.S., Shankar V.S., Bax B.E., Moonga B.S., Bevis P.J.et al. A quantitative description of components of in vitro morphometric change in the rat osteoclast model: relationships with cellular function. Eur. Biophys. J. 21(5):1992;349-355.
2. Chambers T.J., Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J. Clin. Endocrinol. Metab. 57(4):1983;819-824.
3. Yumita S., Nicholson G.C., Rowe D.J., Kent G.N., Martin T.J. Biphasic effect of calcitonin on tartrate-resistant acid phosphatase activity in isolated rat osteoclasts. J. Bone Miner. Res. 6(6):1991;591-597.
4. Moonga B.S., Moss D.W., Patchell A., Zaidi M. Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption. J. Physiol. (Lond.). 429:1990;29-45.
5. Takahashi N., Yamana H., Yoshiki S., Roodman G.D., Mundy G.R., Jones S.J.et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology. 122(4):1988;1373-1382.
6. Nicholson G.C., Horton M.A., Sexton P.M., D'Santos C.S., Moseley J.M., Kemp B.E.et al. Calcitonin receptors of human osteoclastoma. Horm. Metab. Res. 19(11):1987;585-589.
7. Zikan V., Stepan J. Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption. Clin. Chim. Acta. 316(1):2002;63-69.
8. Chesnut C.H., Silverman S., Andriano K., Genant H., Gimona A., Harris S.et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. 109(4):2000;267-276.
9. Singer F.R., Aldred J.P., Neer R.M., Krane S.M., Potts J.T. Jr., Bloch K.J. An evaluation of antibodies and clinical resistance to salmon calcitonin. J. Clin. Invest. 51(9):1972;2331-2338.
10. Levy F., Muff R., Dotti Sigrist S., Dambacher M.A., Fischer J.A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J. Clin. Endocrinol. Metab. 67(3):1988;541-545.
11. Grauer A., Raue F., Schneider H.G., Frank Raue K., Ziegler R. In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin. J. Bone Miner. Res. 5(4):1990;387-391.
12. Rosenquist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Qvist P.et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin. Chem. 44(11):1998;2281-2289.
13. Schlemmer A., Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur. J. Endocrinol. 140(4):1999;332-337.
14. Qvist P., Christgau S., Pedersen B.J., Schlemmer A., Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 31(1):2002;57-61.
15. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos. Int. 11(17):2000;6s2-6s17.
16. Blake G.M., Fogelman I. Monitoring treatment for osteoporosis by using bone densitometry. Semin. Nucl. Med. 31(3):2001;212-222.
17. Clissold S.P., Fitton A., Chrisp P. Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Aging. 1(5):1991;405-423.
18. Foti R., Martorana U., Broggnin M. Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr. Ther. Res. 56:1995;429-435.
19. Silva O.L., Becker K.L. Salmon calcitonin in the treatment of hypercalcemia. Arch. Intern. Med. 132(3):1973;337-339.
20. Inoue D., Shih C., Galson D.L., Goldring S.R., Horne W.C., Baron R. Calcitonin-dependent down-regulation of the mouse C1a calcitonin receptor in cells of the osteoclast lineage involves a transcriptional mechanism. Endocrinology. 140(3):1999;1060-1068.
21. Buclin T., Randin J.P., Jacquet A.F., Azria M., Attinger M., Gomez F.et al. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif. Tissue Int. 41(5):1987;252-258.
22. O'Doherty D.P., Bickerstaff D.R., McCloskey E.V., Atkins R., Hamdy N.A., Kanis J.A. A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin. Sci. (Colch). 78(2):1990;215-219.
23. Overgaard K., Agnusdei D., Hansen M.A., Maioli E., Christiansen C., Gennari C. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J. Clin. Endocrinol. Metab. 72(2):1991;344-349.
24. Thamsborg G., Skousgaard S.G., Daugaard H., Schifter S., Kollerup G., Sorensen O.H. Acute effects of nasal salmon calcitonin on calcium and bone metabolism. Calcif. Tissue Int. 53(4):1993;232-236.
25. Schlemmer A., Ravn P., Hassager C., Christiansen C. Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. Bone. 20(1):1997;63-67.
26. Reginster J.Y., Deroisy R., Lecart M.P., Sarlet N., Zegels B., Jupsin I.et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am. J. Med. 98(5):1995;452-458.
27. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif. Tissue Int. 55(2):1994;82-86.
28. Trovas G.P., Lyritis G.P., Galanos A., Raptou P., Constantelou E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J. Bone Miner. Res. 17(3):2002;521-527.
29. Rand T., Seidl G., Kainberger F., Resch A., Hittmair K., Schneider B.et al. Impact of spinal degenerative changes on the evaluation of bone mineral density with dual energy X-ray absorptiometry (DXA). Calcif. Tissue Int. 60(5):1997;430-433.